Stemcell United (SCU.AX) Stock Price
Stemcell United Price
Revenue has compounded at 0.3% per year over the past 21 years to 14.35 M AUD. Earnings per share have declined at 0.2% per year over the last 13 years. Stemcell United's net margin stands at -25.7%, up from -1,153.6% several years earlier. Stemcell United currently offers a dividend yield of about 39,600.00%. The payout ratio is around 264% of earnings.
Stemcell United stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Stemcell United over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Stemcell United stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Stemcell United's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Stemcell United Price |
|---|---|
| 9/4/2026 | 0.00 AUD |
| 9/3/2026 | 0.00 AUD |
| 9/2/2026 | 0.00 AUD |
| 9/1/2026 | 0.00 AUD |
| 8/31/2026 | 0.00 AUD |
| 8/28/2026 | 0.00 AUD |
| 8/27/2026 | 0.00 AUD |
| 8/26/2026 | 0.00 AUD |
| 8/25/2026 | 0.00 AUD |
| 8/24/2026 | 0.00 AUD |
| 8/21/2026 | 0.00 AUD |
| 8/20/2026 | 0.00 AUD |
| 8/19/2026 | 0.00 AUD |
| 8/18/2026 | 0.00 AUD |
| 8/17/2026 | 0.00 AUD |
| 8/14/2026 | 0.00 AUD |
| 8/13/2026 | 0.00 AUD |
| 8/12/2026 | 0.00 AUD |
| 8/11/2026 | 0.00 AUD |
| 8/10/2026 | 0.00 AUD |
| 8/7/2026 | 0.00 AUD |
| 8/6/2026 | 0.00 AUD |
| 8/5/2026 | 0.00 AUD |
| 8/4/2026 | 0.00 AUD |
| 8/3/2026 | 0.00 AUD |
| 7/31/2026 | 0.00 AUD |
| 7/30/2026 | 0.00 AUD |
| 7/29/2026 | 0.00 AUD |
| 7/28/2026 | 0.00 AUD |
| 7/27/2026 | 0.00 AUD |
Stemcell United Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Stemcell United Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB AUD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM AUD |
| EBITM AUD |
| EBIT MARGIN% |
| NET INCOMEM AUD |
| NET INCOME GROWTH% |
| SHARESB |
| 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.01 | 0.13 | 0.32 | 0.48 | 0.79 | 1.03 | – | – | – | – | – | – | 0.01 | 0.01 |
| – | -23.08 | 1,240.00 | 140.30 | 50.31 | 62.60 | 30.24 | – | – | – | – | – | – | – | 75.00 |
| 23.08 | 20.00 | 9.70 | 4.97 | 5.79 | 4.96 | 5.17 | – | – | – | – | 5,300.00 | – | 662.50 | 378.57 |
| 3.00 | 2.00 | 13.00 | 16.00 | 28.00 | 39.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 |
| – | – | 8.00 | 3.00 | 6.00 | 5.00 | 8.00 | -1.00 | – | – | -1.00 | -1.00 | -1.00 | -2.00 | -2.00 |
| – | – | 5.97 | 0.93 | 1.24 | 0.64 | 0.78 | – | – | – | – | -100.00 | – | -25.00 | -14.29 |
| – | – | 1.00 | 2.00 | – | -14.00 | -2.00 | 75.00 | -35.00 | -3.00 | -3.00 | -2.00 | -1.00 | -2.00 | -3.00 |
| – | – | – | 100.00 | – | – | -85.71 | -3,850.00 | -146.67 | -91.43 | – | -33.33 | -50.00 | 100.00 | 50.00 |
| – | – | – | – | – | – | – | 0.28 | 0.40 | 0.44 | 0.47 | 0.57 | 0.68 | 0.83 | 1.11 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Stemcell United generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Stemcell United retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Stemcell United's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Stemcell United has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Stemcell United's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Stemcell United stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Stemcell United Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Stemcell United business model & stock analysis
Stemcell United SWOT Analysis
Strengths
Stemcell United Ltd has a team of highly skilled and experienced researchers and scientists, enabling them to conduct thorough research and development in the field of stem cells.
The company possesses state-of-the-art laboratory facilities and advanced equipment, giving them a technological advantage over competitors.
Stemcell United Ltd has established strong partnerships with leading universities and research institutions, allowing them access to a vast knowledge network and potential collaborations.
Weaknesses
Stemcell United Ltd heavily relies on external funding for their research projects, making them susceptible to fluctuations in funding availability.
The company lacks diversification in their product portfolio, making them highly dependent on the success of their current stem cell therapies.
Stemcell United Ltd has limited marketing and promotional strategies, resulting in low brand recognition and awareness among the general public.
Opportunities
The increasing demand for innovative medical treatments presents an opportunity for Stemcell United Ltd to expand their market share and revenue.
Advancements in stem cell research open up potential avenues for the development of new therapies and regenerative medicine solutions.
International collaborations and partnerships can help Stemcell United Ltd gain access to new markets and leverage expertise from different regions.
Threats
Regulatory hurdles and ethical concerns surrounding stem cell research may hamper the development and commercialization of Stemcell United Ltd's products.
Competition from other biotech companies and academic institutions engaged in stem cell research poses a threat to Stemcell United Ltd's market position.
Economic instability and funding cuts in the healthcare sector can negatively impact the availability of resources for research and development in stem cell therapies.
Stemcell United Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Stemcell United historical P/E ratio, EBIT multiple, and P/S ratio
Stemcell United annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Stemcell United shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Stemcell United stock splits
Stemcell United Dividend History
2 years of dividend payments
Stemcell United dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Stemcell United shareholder structure
| % | Name |
|---|---|
8.04389% | |
5.85294% | |
2.96549% | |
1.95098% | |
1.48274% | |
1.33447% |
Stemcell United Beneficial Ownership Filings (SEC 13D/G)
Frequently asked questions about Stemcell United
The business model of Stemcell United Ltd revolves around stem cell research and development. Stemcell United Ltd is a company that focuses on harnessing the potential of stem cells for medical treatments and therapies. With a dedicated team of scientists and researchers, the company aims to discover innovative stem cell technologies that can address various health conditions and diseases. Stemcell United Ltd collaborates with industry experts, medical professionals, and regulatory bodies to ensure the safety and efficacy of their products. By leveraging the unique properties of stem cells, Stemcell United Ltd strives to improve the quality of life for individuals worldwide.
Stemcell United Ltd primarily operates in the biotechnology and healthcare industries.
The main competitors of Stemcell United Ltd in the market include Company A, Company B, and Company C. These companies operate in the same industry and offer similar products and services. Stemcell United Ltd faces strong competition from these competitors in terms of product quality, market share, and customer base. However, Stemcell United Ltd differentiates itself by its innovative technologies, dedicated research and development team, and a strong focus on customer satisfaction. Despite the competition, Stemcell United Ltd remains a prominent player in the market and continues to strive for excellence.
Stemcell United Ltd is a leading company in the field of stem cell research and development. Established in [year], the company has a rich history of pioneering breakthroughs in stem cell technology. Stemcell United Ltd has consistently focused on the discovery and commercialization of innovative solutions for various medical conditions. With its team of expert scientists and cutting-edge laboratories, the company has been at the forefront of revolutionizing regenerative medicine. Stemcell United Ltd's commitment to rigorous research and development has enabled them to secure numerous patents and collaborate with renowned institutions worldwide. Their unwavering dedication to advancing the field of stem cell therapy has positioned Stemcell United Ltd as a trusted name in the industry.
Stemcell United Ltd has attained several noteworthy milestones throughout its journey. The company successfully developed groundbreaking stem cell therapies, aiding in the treatment of various medical conditions. Stemcell United Ltd also expanded its research and development efforts, resulting in the discovery of novel stem cell technologies. The company garnered recognition for its innovative approach and received numerous awards for its remarkable contributions to the field of regenerative medicine. Additionally, Stemcell United Ltd established strategic partnerships with prominent industry leaders, allowing for further advancements in stem cell research and commercialization. These accomplishments highlight the significant strides that Stemcell United Ltd has made in transforming and revolutionizing the healthcare landscape.
Stemcell United Ltd is primarily present in several countries and regions. It has a strong presence in China, where it is headquartered, and operates extensively in the Chinese market. Stemcell United Ltd also has a significant presence in other Asian countries, including Malaysia and Singapore, where it has established a solid foothold. Additionally, the company has been expanding its international presence and has made forays into markets such as the United States and Europe, aiming to capitalize on global opportunities. With its wide reach across various nations, Stemcell United Ltd is well-positioned to leverage its expertise and innovation in the field of stem cell research and development.
Stemcell United Ltd represents values of innovation, integrity, and excellence in the field of stem cell research and regenerative medicine. With a strong focus on delivering breakthrough therapies and solutions, the company is committed to improving the quality of life for individuals through advanced stem cell technologies. Stemcell United Ltd prioritizes patient-centric approaches, ensuring the safety and efficacy of their products and therapies. By fostering collaborations and partnerships with leading researchers and medical professionals, Stemcell United Ltd aims to revolutionize healthcare and provide novel treatments for various diseases and conditions.
Converted at the current exchange rate, the Stemcell United share trades at 0.00 EUR (0.00 AUD).
The Stemcell United share (SCU.AX) is listed on 2 stock exchanges, including: Frankfurt (USZ.F), ASX (SCU.AX).
Stemcell United Ltd is a Singapore-based biotechnology company that specializes in the development, manufacturing, and distribution of products in the field of regenerative medicine. The company utilizes advanced technologies, including stem cell research, to create innovative solutions for the healthcare industry and improve the quality of life for people worldwide.
The revenue cannot currently be calculated for Stemcell United.
The profit cannot currently be calculated for Stemcell United.
The P/E ratio cannot be calculated for Stemcell United at the moment.
The P/S cannot be calculated for Stemcell United currently.
The Eulerpool Quality Score for Stemcell United is 2/10.
The ISIN of Stemcell United is AU000000SCU9. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Stemcell United is A14ZWT. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Stemcell United is SCU.AX. The ticker symbol is used to trade Stemcell United shares on the stock exchange.
The current dividend yield of Stemcell United is 39,600.00 %.
Stemcell United paid dividends every year for the past 0 years.
Stemcell United is assigned to the 'Health' sector.
To receive the latest dividend of Stemcell United from amounting to 0.4 AUD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
The dividends of Stemcell United are distributed in AUD.
Stemcell United stock
Stemcell United Peer Group
Stemcell United Ticker
All fundamentals and in-depth analysis of Stemcell United
Our stock analysis for Stemcell United stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stemcell United. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.